| |
See how this AI-powered tool provided the sponsor a real-time competitive landscape evaluation for Immuno-oncology therapies with valuable insights for enhanced decision-making. Read the case study. 
|
|
|
We invite you to join us at the Fierce Medical Affairs Strategic Summit West. Join medical affairs, field medical, and medical communications teams to share best practices, gain actionable insights and crowdsource ideas to their unique challenges from their peers.
Register now
.png)
|
|
| By Nick Paul Taylor AstraZeneca and Daiichi Sankyo’s attempt to repeat the success of Enhertu has delivered its first phase 3 data. The antibody-drug conjugate improved progression-free survival in lung cancer patients but, with the partners yet to share numbers and “some” patients suffering fatal adverse events, shares in AstraZeneca fell almost 6% in early trading in London. |
|
|
|
| July 18-19, 2023 | Jersey City, NJ |  |
|
|
By Kevin Dunleavy A former statistician at Pfizer and his associate have been charged with insider trading, using advance information to make more than $350,000 from stock purchases that they executed one day before the company made trial results public for COVID-19 blockbuster Paxlovid. |
By Angus Liu After an initial rejection in 2020 and a review delay earlier this year, BioMarin’s Roctavian has finally got the FDA go-ahead to introduce a gene therapy for a not-so-rare disorder. |
By James Waldron First-generation mRNA vaccines for flu “will not win,” Sanofi executives have admitted as they set out plans to develop more advanced candidates they believe will overcome the technology’s existing shortfalls. |
By Ayla Ellison Last week, I introduced you to the Fierce 50, a groundbreaking project that celebrates the leaders and visionaries igniting change in healthcare delivery, drug development, research and beyond. Today, I’m unveiling the five categories that will shape this special report. |
By Max Bayer Tessa Therapeutics is closing its doors after reportedly failing to secure additional financing or find a buyer. The company had raised more than $200 million since 2017. |
By Kevin Dunleavy The SEC has revealed insider trading charges against five—including former Alexion vice president Joseph Dupont and a Massachusetts police chief—who allegedly took advantage of prior knowledge of Alexion’s 2020 acquisition of Portola Pharmaceuticals. |
By Annalee Armstrong Once one of the hottest vessels in the pharma fleet, SHP2 inhibitors are starting to retreat from the seas as AbbVie joins the list of companies ending work on a collaboration with Jacobio to develop therapies for the target. |
By Zoey Becker Novartis is passing off the dry eye disease drop Xiidra to eye health specialist Bausch + Lomb in a $2.5 billion deal, another step in the company's overhaul as it focuses on five core areas. |
By Kevin Dunleavy Much attention has been paid to Vertex’s efforts to develop a stem-cell therapy for Type 1 diabetes. But flying under the radar with an allogenic (donor) gene therapy for the disorder has been Chicago startup CellTrans. Thursday, the FDA signed off on CellTrans’ Lantidra (donislecel), the first cell therapy for type 1 diabetes. |
By James Waldron Thermo Fisher Scientific has given a glimpse into how its “disciplined capital deployment strategy” will work in reality, fronting close to a billion dollars to get its hands on real-world data intelligence company CorEvitas. |
By Ben Adams A topical vitiligo treatment, AI-powered radiology and next-gen vaccine manufacturing are just some of the leading biopharma products that have been placed on Clarivate’s Top 100 New Brands report. |
By Helen Floersh A new study from researchers at the University of California San Diego School of Medicine has found one potentially beneficial combo for pancreatic cancer: Mirati Therapeutics' KRAS inhibitor adagrasib, known as Krazati, and Boehringer Ingelheim’s ERBB gene inhibitor afatinib, trade name Gilotrif. |
By Kevin Dunleavy With Pfizer set to launch its biosimilar version of AbbVie’s Humira, the company has expanded its partnership with Samsung Biologics, which will produce biosimilars for the pharma giant at its sprawling complex in South Korea. Samsung said on Monday that Pfizer had added to two biosimilar production agreements the companies had made earlier this year, making the combined total $897 million. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss new HIV therapies, plus Humira's new biosimilar, foreign pharmaceutical investments, and the rest of the week's headlines. |
|
|---|
|
|
Research The right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Best practices from biopharma clinical studies for medical device manufacturers around the efficient collection and use of data to speed insights into product safety and efficacy Sponsored by: Cognizant |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Whitepaper Shave up to six months off the development timeline of a mAb candidate Sponsored by: Curia Global |
eBook This eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
eBook Take a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
Whitepaper Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Modern software development and its impact on addressing clinical trial complexity. Sponsored by: YPrime |
Whitepaper Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
Research There’s a $70 billion growth opportunity for pharma and medtech in transitioning care from the hospital to home. Read our latest report to find out how we can create better patient outcomes and drive health equity. Sponsored by: PA Consulting |
| July 18-19, 2023 | Jersey City, NJ |
|
|
| |
|
